 |
LANA1 (ORF73) expression in a KS lesion. LANA1 has a punctate nuclear localization pattern. |
 |
LANA2 (ORFK10.5) expression in BCBL1 tissue culture cells. The nuclear localization pattern is similar to that of LANA1 but it does not perfectly colocalize with LANA1. |
 |
Comparison of LANA1 and LANA2 expression in Kaposi's sarcoma (KS), Castleman's disease (CD) and primary effusion lymphoma (PEL) tissues. Note that LANA1 is expressed in all KSHV-infected tissues in ethanol and allowed to recrystallize through evaporation. |
 |
vIRF-1 (ORFK9) expression in BCBL1 tissue culture cells. vIRF-1 shuttles between the cytoplasm and the nucleus as shown in these two cells. Although vIRF-1 is readily seen in PEL tissue culture cell lines,it is rarely expressed in PEL tumors. It is expressed in Castleman's disease tumors. |
 |
vIL-6 (ORFK2) expression in the mantle zone of a germinal center in a Castleman's disease (CD) lymph node.vIL-6 is generally not expressed in KS lesions but it is found in both PEL and CD tumors. |
 |
Expression of PF-8 (ORF 59) in Castleman's disease germinal center. PF-8 is expressed during lytic KSHV replication and is rarely seen in PEL or KS tumors but is commonly found in CD tumors. |
References:
1. Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma,primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol 2000; 156:743-9.
2. Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol 2001; 156:743-9.
Operated by the University of California for the National Nuclear Security Administration,
of the US Department of Energy. Copyright © 2001 UC | Disclaimer/Privacy
